Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG
In a clinical-trial update, researchers look into empagliflozin effects on type 2 diabetes patients who have heart failure at study baseline, incident heart failure during the trial, or not at all.Heartwire from Medscape
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
More News: Cardiology | Clinical Trials | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Health | Heart | Heart Failure | Jardiance | Study